Because genome-wide association studies have shown that genetic variations near the Klf14 locus are associated with HDL cholesterol levels, coronary heart disease, and metabolic syndrome (70), therapeutic intervention targeting KLF14 is an attractive strategy for the treatment and prevention of human dyslipidemia and atherosclerosis. Here, KLF14 is linked to atherosclerosis.